New indication for Inegy
Inegy (simvastin, ezetimibe; Merck Sharp & Dohme) is now indicated to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome, either previously treated with a statin or not. Further changes to the summary of product characteristics reflect this addition.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200796
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now